EyeGate Pharma Eye Treatment EGP-437 Fails Phase IIb Trial

EyeGate Pharmaceuticals today acknowledged that its combination treatment EGP-437 (Delivered by Iontophoresis System), envisioned as an alternative to eye drops and injections, has failed a Phase IIb trial in patients with pain and inflammation after undergoing cataract surgery.EGP-437 missed its co-primary endpoints of proportion of subjects with an anterior chamber cell (ACC) count of zero at day 7 and the proportion of subjects with a pain score of zero at day 1.While the combination treatmen